Diabetic Retinopathy Clinical Trials

Find Diabetic Retinopathy Clinical Trials Near You

Multicenter National Parallel Cluster Randomized Controlled Superiority Trial Comparing an Artificial Intelligence-Based Screening Strategy to Usual Care for Improving Eye-Care Follow-Up Among Patients With Diabetes (AI-BRIDGE Trial)

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This pragmatic clinical trial is being conducted to test the effectiveness of AI-BRIDGE (Artificial Intelligence-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education), in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 8 primary care clinics. AI-BRIDGE is an implementation program which includes an autonomous AI-based protocol that provides screening for diabetic retinopathy (DR) disease at primary care visits, as well as patient education on disease and, if a patient screens positive for referable DR or has insufficient quality image, or image unobtainable due to other technical issues, or does not get AI-screening for any reason, assistance with scheduling an in-person, follow-up eye-care visit.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 22
Healthy Volunteers: f
View:

• Clinic must be from a health system with at least two clinics that meet eligibility criteria and will agree to join.

• Number of unique patients with diabetes should be \>550 over any continuous 15-month period prior to the clinic providing a letter of support to participate in the trial.

• No point-of-care screening system in use for DR.

• Have an electronic health record to track patient data and agree to share limited data set as requested.

• Have a member of the clinical team who can commit to serving as the clinic champion for this study.

• Have the IT infrastructure to deploy an artificial-intelligence-based eye camera in the clinic.

• Diagnosis of type 1 or 2 diabetes

• No known diabetic retinopathy

• No diabetic retinopathy screening in the past 12 months

Locations
United States
Wisconsin
UW School of Medicine and Public Health
RECRUITING
Madison
Contact Information
Primary
Mozhdeh Bahrainian
bahrainian@wisc.edu
608-262-9955
Backup
Roomasa Channa
rchanna@wisc.edu
Time Frame
Start Date: 2026-10-01
Estimated Completion Date: 2030-05
Participants
Target number of participants: 6900
Treatments
Active_comparator: Health System 1: Usual Care plus Education
4 month period of usual care screening then randomized to a 15-month period of usual care. Participants in usual care will receive educational material about diabetic retinopathy.
Experimental: Health System 1: AI-BRIDGE Clinic
4 month period of usual care screening then randomized to a 15-month period of AI-based eye screening program called AI-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education (AI-BRIDGE).
Active_comparator: Health System 2: Usual Care plus Education
4 month period of usual care screening then randomized to a 15-month period of usual care. Participants in usual care will receive educational material about diabetic retinopathy.
Experimental: Health System 2: AI-BRIDGE Clinic
4 month period of usual care screening then randomized to a 15-month period of AI-based eye screening program called AI-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education (AI-BRIDGE).
Active_comparator: Health System 3: Usual Care plus Education
4 month period of usual care screening then randomized to a 15-month period of usual care. Participants in usual care will receive educational material about diabetic retinopathy.
Experimental: Health System 3: AI-BRIDGE Clinic
4 month period of usual care screening then randomized to a 15-month period of AI-based eye screening program called AI-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education (AI-BRIDGE).
Active_comparator: Health System 4: Usual Care plus Education
4 month period of usual care screening then randomized to a 15-month period of usual care. Participants in usual care will receive educational material about diabetic retinopathy.
Experimental: Health System 4: AI-BRIDGE Clinic
4 month period of usual care screening then randomized to a 15-month period of AI-based eye screening program called AI-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education (AI-BRIDGE).
Related Therapeutic Areas
Sponsors
Leads: University of Wisconsin, Madison
Collaborators: National Eye Institute (NEI)

This content was sourced from clinicaltrials.gov